Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.

Abstract

1087Background: EGFR overexpression is an independent poor prognostic factor in patients with inflammatory breast cancer (IBC). Our IBC animal model indicated that EGFR-targeted therapy inhibited IBC tumor progression via reversing EMT and suppression of CSC phenotype. We hypothesized that the combination of an anti-EGFR monoclonal antibody to neoadjuvant chemotherapy for IBC produce higher pathological complete response (pCR; including breast and axilla) rates compared with our historic rates (triple-negative [TN], 12%; HR+/HER2-, 7%) of 527 patients. Methods: In this single-arm, phase II study (47 patients enrolled, closed in June 2015), patients received 1 dose of panitumumab in a window period followed by 4 cycles of the combination of panitumumab (2.5 mg/kg), nab-paclitaxel (100 mg/m2), and carboplatin (AUC 2) on a weekly (PNC) followed by 4 cycles of FEC (5-fluorouracil, 500 mg/m2; epirubicin, 100 mg/m2; cyclophosphamide, 500 mg/m2) was administered, followed by surgical resection, radiation, and ho...